Search: (WFRF:(Parekh N))
> (2011-2014) >
Trabectedin plus pe...
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
- Article/chapterEnglish2011
Publisher, publication year, extent ...
-
Elsevier BV,2011
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-148153
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-148153URI
-
https://doi.org/10.1093/annonc/mdq353DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L. P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6-12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy. Patients and methods: A detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted. Results: Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was significantly prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357). Conclusion: The superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by differences in the extent or nature of subsequent therapies administered to these patients. On the other hand, these exploratory analyses support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum.
Subject headings and genre
-
pegylated liposomal doxorubicin
-
platinum-free interval
-
relapsed ovarian cancer
-
trabectedin
-
MEDICINE
-
MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
-
Colombo, N.
(author)
-
Monk, B. J.
(author)
-
Tjulandin, S.
(author)
-
Kong, B.
(author)
-
Roy, M.
(author)
-
Chan, S.
(author)
-
Filipczyk-Cisarz, E.
(author)
-
Hagberg, HansUppsala universitet,Enheten för onkologi(Swepub:uu)hanshagb
(author)
-
Vergote, I.
(author)
-
Lebedinsky, C.
(author)
-
Parekh, T.
(author)
-
Santabarbara, P.
(author)
-
Park, Y. C.
(author)
-
Nieto, A.
(author)
-
Poveda, A.
(author)
-
Uppsala universitetEnheten för onkologi
(creator_code:org_t)
Related titles
-
In:Annals of Oncology: Elsevier BV22:1, s. 49-580923-75341569-8041
Internet link
Find in a library
To the university's database
- By the author/editor
-
Kaye, S. B.
-
Colombo, N.
-
Monk, B. J.
-
Tjulandin, S.
-
Kong, B.
-
Roy, M.
-
show more...
-
Chan, S.
-
Filipczyk-Cisarz ...
-
Hagberg, Hans
-
Vergote, I.
-
Lebedinsky, C.
-
Parekh, T.
-
Santabarbara, P.
-
Park, Y. C.
-
Nieto, A.
-
Poveda, A.
-
show less...
- Articles in the publication
-
Annals of Oncolo ...
- By the university
-
Uppsala University